Taylor Ian

SEC source: 0001655759-25-000050 · wk-form4_1740483206.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,121

F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's RSUs granted on February 22, 2023.

SEC source: 0001655759-25-000050 · wk-form4_1740483206.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,785

F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024.

SEC source: 0001655759-25-000025 · wk-form4_1739926736.xml · derivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,483

Underlying: Common Stock · 31,483 shares

Expires 2035-02-12

F2 · derivative.exercise_date: The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February 13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001655759-25-000025 · wk-form4_1739926736.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,141

F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on February 13, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001655759-24-000025 · wk-form4_1709076814.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,100

Underlying: Common Stock · 58,100 shares

Expires 2034-02-22

F3 · derivative.exercise_date: The option was granted by the Issuer on February 23, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.

SEC source: 0001655759-24-000025 · wk-form4_1709076814.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,522

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

SEC source: 0001655759-24-000025 · wk-form4_1709076814.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,223

F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 23, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting in on February 23, 2026.

SEC source: 0001655759-24-000004 · wk-form4_1704749977.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,065

Underlying: Common Stock · 4,899 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of March 31, 2019, and the remainder of the shares vested in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0001655759-24-000004 · wk-form4_1704749977.xml · derivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,519

Underlying: Common Stock · 3,353 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 28, 2019, and the remainder of the shares vested in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001655759-24-000004 · wk-form4_1704749977.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,973

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001655759-23-000026 · wf-form4_167789825591082.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,685 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

SEC source: 0001655759-23-000026 · wf-form4_167789825591082.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,721

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F3 · price: The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at a price of $29.53.

SEC source: 0001655759-23-000026 · wf-form4_167789825591082.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001655759-23-000017 · wf-form4_167727578035848.xml · derivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,450

Underlying: Common Stock · 57,450 shares

Expires 2033-02-21

F2 · derivative.exercise_date: The option was granted by the Issuer on February 22, 2023, pursuant to the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on February 22, 2024, with the remainder of the shares vesting in equal monthly installments following February 22, 2024 through February 23, 2027.

SEC source: 0001655759-23-000017 · wf-form4_167727578035848.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,087

F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 22, 2023, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 1/4 of the shares underlying the award shall vest on February 22, 2024, with the remainder of the shares vesting in equal monthly installments following February 22, 2024 through February 23, 2027.

SEC source: 0001209191-22-022103 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,962

F1 · kind: Reflects the gift of common stock to a charitable donor advised fund.

SEC source: 0001209191-22-016532 · doc4.xml · derivative · entry 4

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,685

Underlying: Common Stock · 2,686 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

F5 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

SEC source: 0001209191-22-016532 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,962

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F3 · price: The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at an average price of $63.94.

SEC source: 0001209191-22-016532 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,831

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-016031 · doc4.xml · derivative · entry 4

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,964

Underlying: Common Stock · 1,979 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0001209191-22-016031 · doc4.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,872

Underlying: Common Stock · 925 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001209191-22-016031 · doc4.xml · derivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 596 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022.

SEC source: 0001209191-22-016031 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-016532 · doc4.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2032-02-22

F4 · derivative.exercise_date: This option award was granted on February 23, 2022. 1/4 of the shares underlying the award shall vest on February 23, 2023, with the remainder of the shares vesting in equal monthly installments following February 23, 2023 through February 23, 2026.

SEC source: 0001209191-22-011074 · doc4.xml · derivative · entry 8

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,633

Underlying: Common Stock · 20,000 shares

Expires 2029-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option award was granted on March 1, 2019. 1/4 of the shares underlying the award vested on March 1, 2020, with the remainder of the shares vesting in equal monthly installments through March 1, 2023.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 7

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,645

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 6

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,745

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.52 to $76.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 5

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,045

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.16 to $75.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 4

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,886

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.16 to $74.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,012

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.15 to $73.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,778

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.14 to $72.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-22-011074 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

SEC source: 0001209191-21-065327 · doc4.xml · derivative · entry 7

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,633

Underlying: Common Stock · 7,794 shares

Expires 2029-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option award was granted on March 1, 2019. 1/4 of the shares underlying the award vested on March 1, 2020, with the remainder of the shares vesting in equal monthly installments through March 1, 2023.

SEC source: 0001209191-21-065327 · doc4.xml · derivative · entry 6

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,943

Underlying: Common Stock · 12,206 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019 with the remainder of the shares vesting in equal monthly installments through March 31, 2022.

SEC source: 0001209191-21-065327 · doc4.xml · nonDerivative · entry 5

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,645

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.66 to $85.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-065327 · doc4.xml · nonDerivative · entry 4

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,129

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.66 to $84.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-065327 · doc4.xml · nonDerivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,789

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.66 to $83.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-065327 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-065327 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-052443 · doc4.xml · derivative · entry 6

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,149

Underlying: Common Stock · 6,196 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0001209191-21-052443 · doc4.xml · derivative · entry 5

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,797

Underlying: Common Stock · 13,804 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001209191-21-052443 · doc4.xml · nonDerivative · entry 4

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,645

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.26 to $88.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-052443 · doc4.xml · nonDerivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,946

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.23 to $88.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-052443 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,408

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.23 to $87.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-052443 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-025942 · doc4.xml · derivative · entry 6

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,601

Underlying: Common Stock · 15,789 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001209191-21-025942 · doc4.xml · derivative · entry 5

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,211 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020.

SEC source: 0001209191-21-025942 · doc4.xml · nonDerivative · entry 4

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,645

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.31 to $68.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-025942 · doc4.xml · nonDerivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,095

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.31 to $67.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-21-025942 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,545

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.30 to $66.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.